
Paul V. Ward
Examiner (ID: 13921, Phone: (571)272-2909 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1623, 1622 |
| Total Applications | 2552 |
| Issued Applications | 1846 |
| Pending Applications | 195 |
| Abandoned Applications | 548 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18842576
[patent_doc_number] => 20230404980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/033994
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033994
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/033994 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | Oct 18, 2021 | Pending |
Array
(
[id] => 18830785
[patent_doc_number] => 20230399309
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/250287
[patent_app_country] => US
[patent_app_date] => 2021-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 553
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250287
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/250287 | Deuterated hpki kinase inhibitor, and preparation method therefor and use thereof | Oct 14, 2021 | Issued |
Array
(
[id] => 19441185
[patent_doc_number] => 12091425
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Compounds that inhibit MCL-1 protein
[patent_app_type] => utility
[patent_app_number] => 17/501075
[patent_app_country] => US
[patent_app_date] => 2021-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 348411
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/501075 | Compounds that inhibit MCL-1 protein | Oct 13, 2021 | Issued |
Array
(
[id] => 20686575
[patent_doc_number] => 12616703
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-05
[patent_title] => Methods of contraception using nomegestrol acetate and estradiol
[patent_app_type] => utility
[patent_app_number] => 18/031749
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 13763
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 172
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031749
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/031749 | Methods of contraception using nomegestrol acetate and estradiol | Oct 11, 2021 | Issued |
Array
(
[id] => 20671899
[patent_doc_number] => 12612399
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-28
[patent_title] => Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/031045
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 32945
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 798
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031045
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/031045 | Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof | Oct 11, 2021 | Issued |
Array
(
[id] => 18590204
[patent_doc_number] => 11739084
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Synthetic route to scopolamine and/or atropine
[patent_app_type] => utility
[patent_app_number] => 17/450254
[patent_app_country] => US
[patent_app_date] => 2021-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1645
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450254
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/450254 | Synthetic route to scopolamine and/or atropine | Oct 6, 2021 | Issued |
Array
(
[id] => 19187726
[patent_doc_number] => 20240166639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/248393
[patent_app_country] => US
[patent_app_date] => 2021-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248393
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/248393 | Potent and selective compounds as serotonin 1B receptor modulators | Oct 6, 2021 | Issued |
Array
(
[id] => 17576861
[patent_doc_number] => 20220133716
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => RORGAMMA MODULATORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/494458
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22789
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 418
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494458 | RORgamma modulators and uses thereof | Oct 4, 2021 | Issued |
Array
(
[id] => 19372898
[patent_doc_number] => 12064437
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies
[patent_app_type] => utility
[patent_app_number] => 17/490778
[patent_app_country] => US
[patent_app_date] => 2021-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 31054
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17490778
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/490778 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | Sep 29, 2021 | Issued |
Array
(
[id] => 18784708
[patent_doc_number] => 20230372315
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness
[patent_app_type] => utility
[patent_app_number] => 18/246775
[patent_app_country] => US
[patent_app_date] => 2021-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7760
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246775
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246775 | Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness | Sep 26, 2021 | Pending |
Array
(
[id] => 18581462
[patent_doc_number] => 20230263714
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => COSMETIC
[patent_app_type] => utility
[patent_app_number] => 18/043558
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043558
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/043558 | COSMETIC | Sep 23, 2021 | Pending |
Array
(
[id] => 18754077
[patent_doc_number] => 20230357451
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/246284
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -64
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246284
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246284 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | Sep 22, 2021 | Pending |
Array
(
[id] => 17335987
[patent_doc_number] => 20220002318
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/478451
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 580
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478451
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478451 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | Sep 16, 2021 | Abandoned |
Array
(
[id] => 18141774
[patent_doc_number] => 20230015617
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => PHTHALAZINONE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/470703
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470703
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470703 | PHTHALAZINONE DERIVATIVES | Sep 8, 2021 | Abandoned |
Array
(
[id] => 18672989
[patent_doc_number] => 20230310446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => RHO KINASE INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION
[patent_app_type] => utility
[patent_app_number] => 18/024623
[patent_app_country] => US
[patent_app_date] => 2021-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8174
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024623
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024623 | RHO KINASE INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | Sep 6, 2021 | Abandoned |
Array
(
[id] => 17441764
[patent_doc_number] => 20220062269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/465087
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11116
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/465087 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Sep 1, 2021 | Issued |
Array
(
[id] => 19135561
[patent_doc_number] => 11970491
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-30
[patent_title] => N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
[patent_app_type] => utility
[patent_app_number] => 17/462148
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 26360
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17462148
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/462148 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | Aug 30, 2021 | Issued |
Array
(
[id] => 17822663
[patent_doc_number] => 11427601
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-08-30
[patent_title] => Inhibitors of KEAP1-Nrf2 protein-protein interaction
[patent_app_type] => utility
[patent_app_number] => 17/460775
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 215289
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460775
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/460775 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | Aug 29, 2021 | Issued |
Array
(
[id] => 19042259
[patent_doc_number] => 11931332
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
[patent_app_type] => utility
[patent_app_number] => 17/461695
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 44580
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 184
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461695
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/461695 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | Aug 29, 2021 | Issued |
Array
(
[id] => 18994530
[patent_doc_number] => 11911346
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Orally administrated therapeutic for treating mild cognitive impairment (MCI) and improving human cognitive function
[patent_app_type] => utility
[patent_app_number] => 17/459889
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8341
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459889
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/459889 | Orally administrated therapeutic for treating mild cognitive impairment (MCI) and improving human cognitive function | Aug 26, 2021 | Issued |